Literature DB >> 2751025

Elimination of cotinine from body fluids: disposition in smokers and nonsmokers.

N J Haley1, D W Sepkovic, D Hoffmann.   

Abstract

We have evaluated differences in the elimination of cotinine, a major nicotine metabolite, in smokers who quit smoking and never-smokers who were exposed to environmental tobacco smoke (ETS) under controlled conditions. The mean biological half-life of cotinine in urine, collected from the nine smokers was 16.5 +/- 1.2 h, in never-smokers exposed to ETS, 27.3 +/- 1.9 h. Differences in the mode of uptake and absorption of nicotine and possible differences in nicotine metabolism may play roles in the clearance rate differences between smokers and nonsmokers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751025      PMCID: PMC1349908          DOI: 10.2105/ajph.79.8.1046

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  18 in total

1.  Elimination from the body of tobacco products by smokers and passive smokers.

Authors:  D W Sepkovic; N J Haley; D Hoffmann
Journal:  JAMA       Date:  1986-08-15       Impact factor: 56.272

2.  PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data.

Authors:  R C Shumaker
Journal:  Drug Metab Rev       Date:  1986       Impact factor: 4.518

Review 3.  The pulmonary uptake, accumulation, and metabolism of xenobiotics.

Authors:  J R Bend; C J Serabjit-Singh; R M Philpot
Journal:  Annu Rev Pharmacol Toxicol       Date:  1985       Impact factor: 13.820

4.  Validation of self-reported smoking behavior: biochemical analyses of cotinine and thiocyanate.

Authors:  N J Haley; C M Axelrad; K A Tilton
Journal:  Am J Public Health       Date:  1983-10       Impact factor: 9.308

5.  Interindividual variations in drug disposition. Clinical implications and methods of investigation.

Authors:  D D Breimer
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 6.  Assessment of methods to identify sources of interindividual pharmacokinetic variations.

Authors:  E S Vesell; M B Penno
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 7.  Cigarette smoking pharmacokinetics and its relationship to smoking behaviour.

Authors:  T D Darby; J E McNamee; J M van Rossum
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 8.  Smoking and drug metabolism.

Authors:  G W Dawson; R E Vestal
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

9.  Smoking-induced changes in nicotine disposition: application of a new HPLC assay for nicotine and its metabolites.

Authors:  G A Kyerematen; M D Damiano; B H Dvorchik; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1982-12       Impact factor: 6.875

10.  Tobacco sidestream smoke: uptake by nonsmokers.

Authors:  D Hoffmann; N J Haley; J D Adams; K D Brunnemann
Journal:  Prev Med       Date:  1984-11       Impact factor: 4.018

View more
  11 in total

Review 1.  Hair as a biomarker for exposure to tobacco smoke.

Authors:  W K Al-Delaimy
Journal:  Tob Control       Date:  2002-09       Impact factor: 7.552

2.  Dose-independent kinetics with low level exposure to nicotine and cotinine.

Authors:  Neal L Benowitz; Delia Dempsey; Rachel F Tyndale; Gideon St Helen; Peyton Jacob
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

3.  Self-Reported Smoking Compared to Serum Cotinine in Bariatric Surgery Patients: Smoking Is Underreported Before the Operation.

Authors:  Paula J D Wolvers; Sjoerd C Bruin; Willem M Mairuhu; Monique de Leeuw-Terwijn; Barbara A Hutten; Dees P M Brandjes; Victor E A Gerdes
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

4.  Decreasing urinary PAH metabolites and 7-methylguanine after smoking cessation.

Authors:  M Ichiba; A Matsumoto; T Kondoh; M Horita; K Tomokuni
Journal:  Int Arch Occup Environ Health       Date:  2006-01-11       Impact factor: 3.015

5.  The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.

Authors:  Joseph Bloom; Anthony L Hinrichs; Jen C Wang; Linda B von Weymarn; Evan D Kharasch; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

6.  Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: a case-control study.

Authors:  Manal M Hassan; James L Abbruzzese; Melissa L Bondy; Robert A Wolff; Jean-Nicolas Vauthey; Peter W Pisters; Douglas B Evans; Rabia Khan; Renato Lenzi; Li Jiao; Donghui Li
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

7.  The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.

Authors:  A Joseph Bloom; Linda B von Weymarn; Maribel Martinez; Laura J Bierut; Alison Goate; Sharon E Murphy
Journal:  Pharmacogenet Genomics       Date:  2013-12       Impact factor: 2.089

8.  Biomarkers of Exposure Among "Dual Users" of Tobacco Cigarettes and Electronic Cigarettes in Canada.

Authors:  Christine D Czoli; Geoffrey T Fong; Maciej L Goniewicz; David Hammond
Journal:  Nicotine Tob Res       Date:  2019-08-19       Impact factor: 4.244

9.  Cotinine and polycyclic aromatic hydrocarbons levels in the amniotic fluid and fetal cord at birth and in the urine from pregnant smokers.

Authors:  Julia de Barros Machado; José Miguel Chatkin; Aline Rigon Zimmer; Ana Paula Szezepaniak Goulart; Flávia Valladão Thiesen
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

10.  Combination use of paclitaxel and avastin enhances treatment effect for the NSCLC patients with malignant pleural effusion.

Authors:  Nan Qi; Fang Li; Xiaosong Li; Huanrong Kang; Hui Zhao; Nan Du
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.